CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Scotiabank. They set a "sector perform" rating and a $23.00 price target on the stock.
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates [Yahoo! Finance]
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates